Biotech

All Articles

BMS ditches TIGIT, ignoring $200M bank on Agenus bispecific

.Bristol Myers Squibb is actually axing another huge wager from the Caforio period, ending a package...

Nuvation halts BET inhibitor after looking at phase 1 data

.After having a look at phase 1 data, Nuvation Biography has actually decided to stop focus on its o...

' Medical instinct' led FDA specialists to back Zevra's uncommon health condition med

.Zevra Rehabs' rare illness medicine seems to be to be on the road to confirmation this autumn after...

Pfizer takes $230M hit after axing fell short DMD genetics therapy

.Pfizer's period 3 Duchenne muscular dystrophy (DMD) genetics treatment failing has blown a $230 mil...

AC Immune finds 'landmark' prospective in Alzheimer's drug information

.After greater than twenty years of deal with neurodegenerative diseases, Swiss biotech air conditio...

GSK falls ph. 2 HPV injection over lack of best-in-class prospective

.GSK has actually junked a stage 2 individual papillomavirus (HPV) vaccine coming from its pipeline ...

OS Therapies refiles $6M IPO to finance HER2 drug, preclinical ADCs

.OS Therapies are going to list on the NYSE American stock swap this morning through a $6.4 thousand...

ALX's fizzling CD47 feedback cost sends out supply spiraling down

.ALX Oncology's stage 2 stomach cancer response rate has actually diminished. After finding its CD47...

Ionis axes eye ailment coming from targets of Roche-partnered possibility after information let down

.Yet Another of Ionis Pharmaceuticals' vital midphase readouts has actually fallen short of desires,...

Biogen's CEO claimed no high-risk handle 2023. He's ready to become bold

.While Biogen's pharma peers are actually seeking for late-stage assets along with little danger, ch...